Form 4: Lexeo Therapeutics Insider Trades: COO Sells Shares

Lexeo Therapeutics' Chief Operating Officer, Jose Manuel Otero, reported transactions involving the acquisition and sale of company common stock.

Summary

• Jose Manuel Otero, Chief Operating Officer of Lexeo Therapeutics, Inc., engaged in stock transactions on June 29, 2026, and July 1, 2026.
• On June 29, 2026, Otero acquired 12,060 shares of common stock at no cost, increasing his total holdings to 142,148 shares.
• On July 1, 2026, Otero sold 4,666 shares of common stock at a weighted average price of $4.48 per share, reducing his total holdings to 137,482 shares.
• The sale on July 1, 2026, was conducted to cover tax obligations related to the release of performance Restricted Stock Units (RSUs).
• The reported sale price of $4.48 is a weighted average, with actual sale prices ranging from $4.35 to $4.73.
• Otero's holdings include 100,621 RSUs, with each RSU representing a contingent right to one share of common stock.

Sentiment

Score: 5

Explanation: StockSavvy.ai views this as a neutral filing. While an insider sold shares, the reason provided (tax obligations on RSUs) is a common and often unavoidable event, not necessarily a reflection of negative sentiment towards the company's performance or outlook.

Positives

• Acquisition of 12,060 shares of common stock at no cost on June 29, 2026, indicating a potential grant or award.
• Reporting Person's beneficial ownership remains substantial at 137,482 shares after the reported transactions.

Negatives

• Sale of 4,666 shares of common stock on July 1, 2026, reducing the Reporting Person's direct holdings.
• The sale was specifically to cover tax obligations, suggesting a need to liquidate shares to meet financial responsibilities.

Risks

• Potential for further sales by insiders to cover tax liabilities or for personal financial needs.
• The weighted average sale price indicates a range of prices, which could imply market volatility or strategic execution of sales.

Future Outlook

No specific forward-looking statements or guidance are provided in this Form 4 filing, which primarily details past transactions.

Management Comments

• The sale was to cover tax obligations on the release of performance Restricted Stock Units ('RSUs').
• The Reporting Person undertakes to provide upon request by the staff of the Securities and Exchange Commission, the Issuer, or a security holder of the Issuer, full information regarding the number of shares sold at each separate sale price.

Industry Context

StockSavvy.ai notes that Form 4 filings are standard disclosures for insider transactions. While this filing details a sale by a key executive, it is attributed to tax obligations related to RSU vesting, which is a common occurrence and not necessarily indicative of a negative view on the company's future prospects.

Stakeholder Impact

• Shareholders: The sale of shares by an executive may be perceived negatively, but the stated reason (tax obligations) mitigates this concern. The remaining substantial holdings by the COO suggest continued commitment.
• Employees: The transaction relates to executive compensation and RSU vesting, which is a standard component of employee incentive structures.
• Management: The transaction reflects the standard management of equity-based compensation and associated tax liabilities.

Next Steps

• The Reporting Person may provide further details on sale prices upon request from regulatory bodies, the issuer, or security holders.

Key Dates

Keywords

Lexeo Therapeutics, LXEO, Form 4, Insider Trading, Stock Sale, Restricted Stock Units, RSU, Jose Manuel Otero, Chief Operating Officer, Beneficial Ownership